UK biotech trade associations join forces

bia-steve-bates web Four organisations representing UK biotechnology companies have entered a formal collaboration to support the UK life sciences industry.

The BioIndustry Association (BIA), Bionow, BioPartner UK and One Nucleus will work together to develop a life science manifesto for the next government.

The partners will also run a series of workshops and webinars to assist the business development of UK bioscience companies.

The four organisations’ support networks for member companies will be aligned, strengthening the sector’s cohesion nationally as well as raising its profile.

The decision builds on the successful joint campaign for the renewal of the Biomedical Catalyst, a translational funding programme for SMEs and academics seeking to develop innovative healthcare solutions.

The success of the BIA and BioPartner in working with UK Trade & Investment (UKTI) to support biotech trade missions to Australia, Brazil, China, India and the USA will be built on by the four partners together with UKTI.

Steve Bates (pictured), CEO of BIA, commented: “Gaining sector input into this collaborative bioscience manifesto for the 2015–20 parliament will ensure that the BIA’s effective lobbying voice is focused on the issues that matter to the sector. Working in partnership with Bionow, BioPartner and One Nucleus around the country will ensure all voices in the sector are heard.”

“BioPartner works with the BIA and major UK life science networks to provide support to all UK companies who wish to internationalise,” said Lin Bateson, Executive Director of BioPartner. “We welcome the BIA’s inclusive and progressive approach over the past year, which enables our members to contribute to policy and benefit from its lobbying and strategic influence.”

The BIA is the UK trade association for bioscience companies. Bionow and One Nucleus represent the biomedical industry in the north and east of England respectively. BioPartner promotes international partnering for trade, investment and collaboration with UK life science companies.